Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
3(50%)
Results Posted
100%(2 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_3
3
50%
Ph phase_1
3
50%

Phase Distribution

3

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 3Large-scale testing
3(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

3

trials recruiting

Total Trials

6

all time

Status Distribution
Active(3)
Completed(2)
Terminated(1)

Detailed Status

Recruiting3
Completed2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
3
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (50.0%)
Phase 33 (50.0%)

Trials by Status

terminated117%
completed233%
recruiting350%

Recent Activity

3 active trials
Showing 5 of 6
recruitingphase_3

A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

NCT06963827
recruitingphase_3

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

NCT06948318
recruitingphase_3

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

NCT06722235
completedphase_1

A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy

NCT05174221
terminatedphase_1

A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT04776018
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06963827Phase 3

A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

Recruiting
NCT06948318Phase 3

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Recruiting
NCT06722235Phase 3

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Recruiting
NCT05174221Phase 1

A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy

Completed
NCT04776018Phase 1

A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

Terminated
NCT03439280Phase 1

A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6